Background: IgA nephropathy (IgAN) is a very common glomerulonephritis worldwide. Nevertheless, treatment options for primary IgAN are still largely based on opinion or weak evidence. There is a lack of large randomized controlled trials (RCT) that provide a definitive immunosuppressive protocol for IgAN. The recent KDIGO Clinical Practice Guidelines for Glomerulonephritis have assigned low levels of evidence for almost all recommendations and suggestions related to this nephropathy. Summary: In this article, we review different treatment options and emphasize that the key to therapeutic decision-making is the assessment of an individual's prognosis. The risk of disease progression is closely related to clinical parameters such as proteinuria, hypertension, and impaired glomerular filtration rate. For patients with minor urinary abnormalities, the mainstay of treatment is long-term regular follow-up to detect renal progression and hypertension. Optimized supportive care aiming to maintain proteinuria <1 g/day is preferred in the typical patient presenting with microhematuria, significant but nonnephrotic proteinuria, hypertension, and variable degrees of renal failure. The atypical patient with overt nephritic syndrome or rapidly progressive kidney injury that represents a vasculitic form of IgAN should be treated with immunosuppression. Finally, the variant of overlapping syndrome of IgAN and lipoid nephrosis that runs a good prognosis should be treated as lipoid nephrosis. Key Message: The treatment of IgAN should be structured according to the clinical scenario.

Keywords:
IgA nephropathy, Treatment, Immunosuppression, Corticosteroid, Renin-angiotensin blockade
1.
Cheng J, Zhang W, Zhang XH, He Q, Tao XJ, Chen JH: ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials. Int J Clin Pract 2009;63:880-888.
2.
Cheng J, Zhang X, Tian J, Li Q, Chen J: Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis. Int J Clin Pract 2012;66:917-923.
3.
Reid S, Cawthon PM, Craig JC, Samuels JA, Molony DA, Strippoli GF: Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev 2011;CD003962.
4.
Tang SC, Lin M, Tam S, Au WS, Ma MK Yap DY, Ho YW, Lai KN: Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study. Nephrol Dial Transplant 2012;27; 613-618.
5.
Szeto CC, Kwan BC, Chow KM, Leung CB, Li PK: The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin A nephropathy - a randomized cross-over study. PLoS One 2013;8:e62736.
6.
Lai KN, To WY, Li PK, Leung JC: Increased binding of polymeric lambda-IgA to cultured human mesangial cells in IgA nephropathy. Kidney Int 1996;49:839-845.
7.
Tang SC, Lai KN: The ubiquitin-proteasome pathway and IgA nephropathy: a novel link? Kidney Int 2009;75:457-459.
8.
Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA: Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials. Nephrology (Carlton) 2004;9:177-185.
9.
Kobayashi Y, Fujii K, Hiki Y, Tateno S: Steroid therapy in IgA nephropathy: a prospective pilot study in moderate proteinuric cases. Q J Med 1986;61:935-943.
10.
Kobayashi Y, Hiki Y, Kokubo T, Horii A, Tateno S: Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. Nephron 1996;72:237-242.
11.
Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F: Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999;353:883-887.
12.
Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F: Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004;15:157-163.
13.
Lai KN, Lai FM, Ho CP, Chan KW: Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol 1986;26:174-180.
14.
Cheng J, Zhang X, Zhang W, He Q, Tao X, Chen J: Efficacy and safety of glucocorticoids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials. Am J Nephrol 2009;30:315-322.
15.
Zhou YH, Tang LG, Guo SL, Jin ZC, Wu MJ, Zang JJ, Xu JF, Wu CF, Qin YY, Cai Q, Gao QB, Zhang SS, Yu DH, He J: Steroids in the treatment of IgA nephropathy to the improvement of renal survival: a systematic review and meta-analysis. PLoS One 2011;6:e18788.
16.
Lv J, Xu D, Perkovic V, Ma X, Johnson DW, Woodward M, Levin A, Zhang H, Wang H; TESTING Study Group: Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol 2012;23:1108-1116.
17.
Radhakrishnan J, Cattran DC: The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines - application to the individual patient. Kidney Int 2012;82:840-856.
18.
Coppo R, Troyanov S, Bellur S, et al: Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int 2014;86:826-836.
19.
Working Group of the International IgA Nephropathy Network and the Renal Pathology Society: The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009;76:546-556.
20.
Tesar V, Troyanov S, Bellur S, et al: Corticosteroid in IgA nephropathy: a retrospective analysis from the VALIGA study. J Am Soc Nephrol 2015, Epub ahead of print.
21.
Ballardie FW, Roberts IS: Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002;13:142-148.
22.
Tumlin JA, Lohavichan V, Hennigar R: Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant 2003;18:1321-1329.
23.
Rasche FM, Klotz CH, Czock D, Karges W, Muche R, Jehle PM, Mertz A, Keller F: Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy. Nephron Clin Pract 2003;93:c131-c136.
24.
Mitsuiki K, Harada A, Okura T, Higaki J: Histologically advanced IgA nephropathy treated successfully with prednisolone and cyclophosphamide. Clin Exp Nephrol 2007;11:297-303.
25.
Moriyama T, Nitta K: Tonsillectomy and steroid pulse therapy for IgA nephropathy. Tohoku J Exp Med 2011;224:243-250.
26.
Wang Y, Chen J, Wang Y, Chen Y, Wang L, Lv Y: A meta-analysis of the clinical remission rate and long-term efficacy of tonsillectomy in patients with IgA nephropathy. Nephrol Dial Transplant 2011;26:1923-1931.
27.
Piccoli A, Codognotto M, Tabbi MG, Favaro E, Rossi B: Influence of tonsillectomy on the progression of mesangioproliferative glomerulonephritis. Nephrol Dial Transplant 2010;25:2583-2589.
28.
Kovacs T, Vas T, Kovesdy CP, Degrell P, Nagy G, Rekasi Z, Wittmann I, Nagy J: Effect of tonsillectomy and its timing on renal outcomes in Caucasian IgA nephropathy patients. Int Urol Nephrol 2014;46:2175-2182.
29.
Nakata J, Suzuki Y, Suzuki H, Sato D, Kano T, Yanagawa H, Matsuzaki K, Horikoshi S, Novak J, Tomino Y: Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy. PLoS One 2014;9:e89707.
30.
Sato Y, Ishida H, Shimizu T, Tanabe K: Evaluation of tonsillectomy before kidney transplantation in patients with IgA nephropathy. Transpl Immunol 2014;30:12-17.
31.
Kawamura T, Yoshimura M, Miyazaki Y, et al: A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transpl 2014;29:1546-1553.
32.
Chen Y, Tang Z, Wang Q, Yu Y, Zeng C, Chen H, Liu ZH, Li LS: Long-term efficacy of tonsillectomy in Chinese patients with IgA nephropathy. Am J Nephrol 2007;27:170-175.
33.
Lai KN, Lai FM, Li PK, Vallance-Owen J: Cyclosporin treatment of IgA nephropathy: a short term controlled trial. Br Med J 1987;295:1165-1168.
34.
Liu H, Xu X, Fang Y, Ji J, Zhang X, Yuan M, Liu C, Ding X: Comparison of glucocorticoids alone and combined with cycloporine A in patients with IgA nephropathy: a prospective randomized controlled trial. Intern Med 2014;53:675-681.
35.
Xu L, Liu ZC, Guan GJ, Lv XA, Luo Q: Cyclosporine A combined with medium/low dose prednisone in progressive IgA nephropathy. Kaohsiung J Med Sci 2014;30:390-395.
36.
Zhang Q, Shi SF, Zhu L, Lv JC, Liu L, Chen Y, Zhang H, Wang H: Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy. Am J Nephrol 2012;35:312-320.
37.
Kim YC, Chin HJ, Koo HS, Kim S: Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: a double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy. PLoS One 2013;8:e71545.
38.
Goumenos DS, Davlouros P, El Nahas AM, Ahuja M, Shortland JR, Vlachojannis JG, Brown CB: Prednisolone and azathioprine in IgA nephropathy - a ten-year follow-up study. Nephron Clin Pract 2003;93:C58-C68.
39.
Yoshikawa N, Ito H: Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy - is it relevant for adult patients? Nephrol Dial Transplant 1999;14:1097-1099.
40.
Pozzi C, Andrulli S, Pani A, Del Vecchio L, Fogazzi G, Vogt B, De Cristofaro V, Allegri L, Cirami L, Procaccini AD, Locatelli F: Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 2010;21:1783-1790.
41.
Pozzi C, Andrulli S, Pani A, Scaini P, Roccatello D, Fogazzi G, Pecchini P, Rustichelli R, Finocchiaro P, Del Vecchio L, Locatelli F: IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroid and azathioprine. J Nephrol 2013;26:86-93.
42.
Chen X, Chen P, Cai G, Wu J, Cui Y, Zhang Y, Liu S, Tang L: A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy (in Chinese). Zhonghua Yi Xue Za Zhi 2002;82:796-801.
43.
Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, Van Damme B, Vanrenterghem YF: Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004;65:1842-1849.
44.
Frisch G, Lin J, Rosenstock J, Markowitz G, D'Agati V, Radhakrishnan J, Preddie D, Crew J, Valeri A, Appel G: Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 2005;20:2139-2145.
45.
Tang S, Leung JC, Chan LY, Lui YH, Tang CS, Kan CH, Ho YW, Lai KN: Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005;68:802-812.
46.
Tang SC, Tang AW, Wong SS, Leung JC, Ho YW, Lai KN: Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 2010;77:543-549.
47.
Roccatello D, Rossi D, Marletto F, Naretto C, Sciascia S, Baldovino S, Piras D, Giachino O: Long-term effects of methylprednisolone pulses and mycophenolate mofetil in IgA nephropathy patients at risk of progression. J Nephrol 2012;25:198-203.
48.
Liu X, Dewei D, Sun S, Xu G, Liu H, He L, Zhang P: Treatment of severe IgA nephropathy: mycophenolate mofetil/prednisone compared to cyclophosphamide/ prednisone. Int J Clin Pharmacol Ther 2014;52:95-102.
49.
Xie L, Tan C, Fan J, Fu P, Tang Y, Tao Y, Qin W: Mycophenolic acid reverses IgA1 aberrant glycosylation through up-regulating Cosmc expression in IgA nephropathy. Int Urol Nephrol 2013;45:571-579.
50.
Lai KN: Pathogenesis of IgA nephropathy. Nat Rev Nephrol 2012;8:275-283.
51.
Xiao J, Leung JC, Chan LY, Tang SC, Lai KN: Crosstalk between peroxisome proliferator-activated receptor-gamma and angiotensin II in renal tubular epithelial cells in IgA nephropathy. Clin Immunol 2009;132:266-276.
52.
Lai KN, Chan LY, Guo H, Tang SC, Leung JC: Additive effect of PPAR-gamma agonist and ARB in treatment of experimental IgA nephropathy. Pediatr Nephrol 2011;26:257-266.
53.
Smerud HK, Barany P, Lindstrom K, Fernström A, Sandell A, Påhlsson P, Fellström B: New treatment of IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant 2011;26:3237-3242.
54.
Moriyama T, Oshima Y, Tanaka K, Iwasaki C, Ochi A, Itabashi M, Takei T, Uchida K, Nitta K: Statins stablize the renal function of IgA nephropathy. Ren Fail 2014;36:356-360.
55.
Maillard N, Wyatt RJ, Julian BA, Kiryluk K, Gharavi A, Fremeaux-Bacchi V, Novak J: Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol 2015, Epub ahead of print.
56.
Rosenblad T Rebetz J, Johansson M, Bekassy Z, Sartz L, Karpman D: Eculizumab treatment for rescue of renal function in IgA nephropathy. Pediatr Nephrol 2014;29:2225-2228.
57.
Kim MJ, McDaid JP, McAdoo SP, Barratt J, Molyneux K, Masuda ES, Pusey CD, Tam FW: Spleen tyrosine kinase is important in the production of proinflammatory cytokines and cell proliferation in human mesangial cells following stimulation with IgA1 isolated from IgA nephropathy patients. J Immunol 2012;189:3751-3758.
58.
Lai KN, Lai FM, Chan KW, Ho CP, Leung AC, Vallance-Owen J: An overlapping syndrome of IgA nephropathy and lipoid nephrosis. Am J Clin Pathol 1986;86:716-723.
59.
Wang J, Juan C, Huang Q, Zeng C, Liu Z: Corticosteroid therapy in IgA nephropathy with minimal change-like lesions: a single-centre cohort study. Nephrol Dial Transplant 2013;28:2339-2345.
60.
Lai KN (ed): A Practical Manual of Renal Medicine. Hong Kong, World Scientific, 2009, pp 115-119.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.